#China #Zhejiang #GMP Production #PharmaBlock #Peptide Plant

PharmaBlock Unveils First GMP Peptide Pilot-Scale Plant

PharmaBlock Sciences has officially launched its first pilot-scale Good Manufacturing Practice (GMP) facility dedicated to peptide production at its Zhejiang manufacturing site. This strategic move marks a significant advancement for the company, aiming to meet the evolving needs of clients in peptide drug development.

Background and Importance

As the pharmaceutical industry increasingly focuses on peptide therapeutics and conjugates, PharmaBlock has recognized the growing demand for robust downstream processing and manufacturing capabilities. The new pilot-scale GMP plant is designed to seamlessly transition client projects from early-stage research and development (R&D) and kilogram-scale GMP manufacturing to more extensive pilot-scale production.

Comprehensive Facility Features

The recently commissioned facility boasts an impressive suite of integrated capabilities:

1. Core Synthesis Platform: The plant is equipped with a cluster of solid-phase peptide synthesis (SPPS) reactors, totaling 600 liters in volume, with configurations of 100, 200, and 300 liters. This versatile setup caters to various process needs, facilitating production campaigns exceeding 10 kilograms while ensuring batch-to-batch consistency through automated fluid handling systems and high-purity inert gas protection.

2. Full-Chain Processing: The facility encompasses advanced cleavage and purification systems built with corrosion-resistant materials for encapsulated processing, maximizing purity and safety during operations. Additionally, high-speed centrifuges and large-scale drying ovens support significant post-processing demands.

3. Cleanroom Standards: Designed in accordance with Grade D and Class C cleanroom regulations, the facility features segregated areas conducive to effective production control—ensuring meticulous control over critical downstream processes like purification and lyophilization of peptide active pharmaceutical ingredients (APIs).

4. Advanced Preparative Chromatography: This plant includes high-resolution preparative purification platforms equipped with GMP-compliant designs tailored to complex purification environments.

5. Intelligent Lyophilization: The integration of a fully automatic lyophilizer enhances the facility's capabilities, providing precise control over the lyophilization process and ensuring consistent reliability and stability.

Vision for Future Development

Dr. Minmin Yang, Chairman of PharmaBlock Group, emphasized that the commissioning of this plant is a major step forward in PharmaBlock's strategy to delve into new molecular modalities. Since its inception in 2008, PharmaBlock has focused on developing unique building block designs that provide a competitive edge. After going public in 2017, the company has accelerated its platform upgrades to include new modalities such as oligonucleotides and peptides, culminating in the establishment of the OPC (Oligonucleotides, Peptides, Conjugates) Division.

In the peptide segment, PharmaBlock is leveraging its extensive expertise and proven synthesis capabilities to offer innovative chemical solutions for peptide and peptide-conjugate projects. Through their extensive library of unnatural amino acids and advanced synthetic technologies rooted in green chemistry, the company has established a significant advantage in the field.

Furthermore, PharmaBlock's Next-Generation Peptide CRDMO (Contract Research, Development, and Manufacturing Organization) Platform integrates a range of state-of-the-art technologies, including liquid-phase peptide synthesis (LPPS), continuous-flow LPPS (CF-LPPS), and enzyme-assisted peptide synthesis (EAPS). This paradigm shift allows for customized manufacturing processes tailored to each client's specific peptide structures.

Conclusion

With the launch of this advanced pilot-scale GMP plant, PharmaBlock is better equipped to contribute to the growing demand for innovative drug development, setting a new standard in peptide production while upholding the values of sustainability and efficiency in pharmaceutical manufacturing.